Like many other large med-tech companies, Abbott Labs (NYSE: ABT )
remains an exercise in frustration right now. There are pressures
throughout most of the company's business lines, with only the
diagnostics business really showing much growth. Although Abbott's
results were a bit weak compared to expectations, analysts and investors
knew that the company was going to go through this lull and longer-term
expectations are still fairly bullish.
Continue here for the full article:
Abbott Labs Earnings: Still Marking Time
No comments:
Post a Comment